Despite decreases in heart failure (HF) incidence and mortality rates in ambulatory patients, mortality remains higher for women, according to a new study published July 16 in the Canadian Medical Association Journal.
Stem cells can be used to “encourage” better function in heart failure (HF) patients in the U.K., according to a recent stem cell therapy trial spearheaded by researchers from the University of Edinburgh. Harvested from bone marrow, the stem cells, which were able to generate new cardiac tissue and blood vessels, had a success rate of 80 percent.
Despite guidelines and quality improvement efforts, many people with heart failure with reduced ejection fraction (HFrEF) aren’t prescribed the recommended medications. And among those who are, fewer than one-fourth receive optimal doses, according to a registry analysis of ambulatory patients.
In the U.S., candidates for heart transplantation are prioritized by the intensity of treatment they’ve received, potentially leading some centers to overtreat patients.
The FDA on Friday, July 13, joined more than 20 other countries in recalling medications containing valsartan, an active ingredient used to treat hypertension and heart failure. Some of the medications with valsartan have been contaminated with N-nitrosodimethylamine (NDMA), a probable human carcinogen.
A new study, published July 11 in the Journal of the American Medical Association, suggests heart failure (HF) may be moderately hereditary.
The FDA has cleared a less-invasive implant approach for Medtronic’s HeartWare HVAD system, allowing the left ventricular assist device (LVAD) to be placed through a small incision between the ribs. It is the first LVAD approved in the U.S. to be inserted with this technique, according to Medtronic.
Scientists are beginning to explore whether infusing heart tissue with mitochondria can restore function to oxygen-deprived cells after a heart attack. The technique has potential in both pediatric and adult patients, according to an article in The New York Times.
New research published in the Journal of the American Medical Association suggests an association between black postmenopausal women who are carriers of apolipoprotein L1 (APOL1) genotypes and hospitalizations for heart failure with preserved ejection fraction (HFpEF). The findings, however, do not support an association between APOL1 genotypes and coronary heart disease, stroke or mortality.
Human stem cells helped restore left ventricular ejection fraction (LVEF) in monkeys induced with experimental heart failure, giving scientists hope a similar treatment could work in humans following myocardial infarction.
The thinking behind the Seattle Proportional Risk Model goes like this: As the annual risk for all-cause mortality increases, the likelihood that the death will be sudden—or something an ICD could prevent—goes down.
A pair of point/counterpoint articles published online June 25 in JACC: Heart Failure debated whether the Hospital Readmissions Reduction Program (HRRP) has resulted in greater mortality for heart failure patients or whether those observations stem from incomplete or misconstrued evidence.
Two nonprofits in the Philadelphia area have joined forces to deliver personalized meals to Medicaid beneficiaries.
Just a week after Baylor St. Luke’s Medical Center in Houston reopened its heart transplant program, CMS sent a letter to the hospital saying it will cut off funding for the program beginning Aug. 17.
Continuing cardiac resynchronization therapy (CRT) appeared to offer no benefit to patients who received a continuous flow left ventricular assist device (CF-LVAD), according to a multicenter study published in the Journal of the American Heart Association.
Jun 22, 2018 | Heart Failure
Heart failure patients treated at hospitals with lower 30-day mortality rates also enjoy a survival benefit one, three and even five years later, suggesting a short-term risk-standardized mortality rate (RSMR) may deserve additional weight in CMS’s financial incentive programs.
Heart Failure, Healthcare Economics & Policy, Practice Management
Jun 18, 2018 | Heart Failure
Baylor St. Luke’s Medical Center in Houston reopened its heart transplant program June 15 after a two-week suspension in which the hospital conducted an internal review of two recent patient deaths.
Heart Failure, Practice Management
Jun 11, 2018 | Heart Failure
Scientists are researching how to take stem cells from the patient’s blood to repair damage to the heart. A new therapy could reduce the need for operations, the U.K.’s Express newspaper reports, with researchers hoping the therapy could save lives while being cost effective. 
Heart Failure
Jun 11, 2018 | Imaging
A scientist at the American Society of Clinical Oncology (ASCO)’s annual meeting discussed how cardiac imaging and biomarker measurements could improve care for cancer survivors.
Imaging, Heart Failure
Patients who progressed to having longer episodes of subclinical atrial fibrillation (SCAF) were more than four times as likely to be hospitalized for heart failure in a one-year span, according to a study published June 4 in the Journal of the American College of Cardiology.
Electrophysiology & Arrhythmia, Heart Failure
Jun 08, 2018 | Heart Failure
Measurements of malnutrition offer incremental prognostic value for patients with heart failure, but more work is needed to tease out which components of the condition are most crucial to calculate and treat, researchers reported in JACC: Heart Failure.
Heart Failure